NASDAQ:BCTX Briacell Therap (BCTX) Stock Price, News & Analysis $3.72 -0.16 (-4.12%) As of 03:49 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Briacell Therap Stock (NASDAQ:BCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Briacell Therap alerts:Sign Up Key Stats Today's Range$3.66▼$3.8950-Day Range$3.02▼$4.6252-Week Range$2.98▼$36.90Volume167,361 shsAverage Volume387,898 shsMarket Capitalization$26.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Read More Briacell Therap Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreBCTX MarketRank™: Briacell Therap scored higher than 4% of companies evaluated by MarketBeat, and ranked 829th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBriacell Therap has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBriacell Therap has only been the subject of 1 research reports in the past 90 days.Read more about Briacell Therap's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Briacell Therap is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Briacell Therap is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBriacell Therap has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.56% of the float of Briacell Therap has been sold short.Short Interest Ratio / Days to CoverBriacell Therap has a short interest ratio ("days to cover") of 2.59, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Briacell Therap has recently increased by 108.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBriacell Therap does not currently pay a dividend.Dividend GrowthBriacell Therap does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Briacell Therap this week, compared to 2 articles on an average week.Search Interest2 people have searched for BCTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Briacell Therap to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Briacell Therap insiders have not sold or bought any company stock.Percentage Held by Insiders0.74% of the stock of Briacell Therap is held by insiders.Percentage Held by Institutions15.42% of the stock of Briacell Therap is held by institutions.Read more about Briacell Therap's insider trading history. Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Briacell Therap and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCTX Stock News HeadlinesBriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™May 15, 2026 | globenewswire.comBriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate CancerMay 14, 2026 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 21 at 1:00 AM | Profits Run (Ad)BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyMay 13, 2026 | markets.businessinsider.comBriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyMay 13, 2026 | globenewswire.comBriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 PatientsMay 12, 2026 | globenewswire.comBriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyMay 7, 2026 | markets.businessinsider.comBriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyMay 7, 2026 | globenewswire.comSee More Headlines BCTX Stock Analysis - Frequently Asked Questions How have BCTX shares performed this year? Briacell Therap's stock was trading at $7.11 at the beginning of the year. Since then, BCTX shares have decreased by 46.5% and is now trading at $3.8030. How were Briacell Therap's earnings last quarter? Briacell Therap (NASDAQ:BCTX) posted its earnings results on Tuesday, March, 10th. The company reported ($2.58) earnings per share for the quarter. When did Briacell Therap's stock split? Briacell Therap's stock reverse split before market open on Tuesday, August 26th 2025.The 1-10 reverse split was announced on Tuesday, August 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Briacell Therap IPO? Briacell Therap (BCTX) raised $15 million in an IPO on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Briacell Therap? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Briacell Therap own? Based on aggregate information from My MarketBeat watchlists, some other companies that Briacell Therap investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Plug Power (PLUG), Micron Technology (MU) and Permian Basin Royalty Trust (PBT). Company Calendar Last Earnings3/10/2026Today5/21/2026Fiscal Year End7/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 6 days, BCTX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCTX CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees8Year Founded2004Profitability EPS (Trailing Twelve Months)($23.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-173.08% Return on Assets-139.64% Debt Debt-to-Equity RatioN/A Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.20 per share Price / Book0.40Miscellaneous Outstanding Shares7,251,000Free Float7,197,000Market Cap$26.94 million OptionableNo Data Beta1.26 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:BCTX) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Briacell Therap Please log in to your account or sign up in order to add this asset to your watchlist. Share Briacell Therap With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
